Kite Pharma names new senior VP of Supply Chain
pharmafile | December 1, 2016 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | appointment, kite pharma
Santa-Monica-based clinical-stage biopharmaceutical firm Kite Pharma has appointed Dr Jian Irish as senior vice president of Supply Chain, who will assume responsibilities of all areas associated with the company’s supply chain, including sourcing, logistics, procurement, inventory management, supply and operations planning process.
Irish’s primary remit will centre around the creation of efficient operational strategies for supply chain design, product lifestyle management, launch and commercialisation. These responsibilities will prove especially important as the company awaits FDA approval of its lead candidate KTE-C19, an investigational T-cell cancer therapy.
Irish’s last role was VP of Biologics Strategic Supply, Sourcing and Partnerships; earlier in her tenure with the company she also served as VP of Biologics Product Development Technology Transfer, while earlier in her career she held a similar supply chain management role at Amgen.
“Jian brings a wealth of supply chain and product development experience to Kite, as well as extensive international business acumen,” commented Tim Moore, executive VP, Technical Operations at Kite. “Her willingness to embrace new opportunities to innovate, coupled with her ability to partner and cultivate talent, makes Jian a great addition to the Technical Operations senior leadership team.”
Dr Irish said of her own appointment: “Coming from a family of medical doctors, I learned from a very young age to appreciate the power that medicine has to change lives. I am excited to be a part of Kite, a company that is increasingly recognized for its leadership in CAR-T therapy as well as its drive to find a cure for cancer. I look forward to partnering with a stellar team of experienced professionals who have a common commitment to excellence at every level.”
Matt Fellows
Related Content
David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.
EMA’s CHMP recommends conditional approval for Kite Pharma’s CAR T therapy for mantle cell lymphoma
Kite Pharma’s anti-CD19 chimeric antigen receptor (CAR) T cell therapy known as KTE-X19 has received …
Kite secures FDA approval for second CAR T therapy Tecartus in relapsed or refractory mantle cell lymphoma
Kite Pharma has chalked up another regulatory success for its parent company Gilead with the …
